BRAF and neoplasm: Sorafenib, an orally active multikinase inhibitor with effects on tumor-cell proliferation and tumor angiogenesis, was initially identified as a Raf kinase inhibitor, by inhibiting the serine-threonine kinase Raf-1 and B-Raf.